LENZ Therapeutics, Inc. (LENZ)
NasdaqGS · USD · Healthcare · Biotechnology
$3.15 (-0.47%) as of
Key statistics
- Market cap
- 98.82M
- Forward P/E
- -1.15
- EPS (TTM)
- -4.1300
- Dividend yield
- 0.00%
- 52-week range
- 3.0600 – 32.9170
- Beta
- 1.73
- Revenue (TTM)
- 21.48M
- Profit margin
- 0.00%
- Analyst target
- $20.00
- Volume
- 389.14k
About LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Solana Beach, CA, United States
- Employees
- 152
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.